Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 28, 2022

SELL
$0.16 - $0.47 $22,290 - $65,478
-139,317 Closed
0 $0
Q1 2022

Apr 13, 2022

BUY
$0.42 - $0.62 $3,612 - $5,332
8,601 Added 6.58%
139,317 $65,000
Q4 2021

Feb 01, 2022

BUY
$0.56 - $1.71 $2,728 - $8,331
4,872 Added 3.87%
130,716 $74,000
Q3 2021

Oct 25, 2021

BUY
$1.21 - $1.8 $36,665 - $54,543
30,302 Added 31.72%
125,844 $208,000
Q2 2021

Jul 21, 2021

BUY
$1.56 - $1.98 $53,210 - $67,535
34,109 Added 55.52%
95,542 $155,000
Q1 2021

May 04, 2021

SELL
$1.36 - $2.49 $68,482 - $125,383
-50,355 Reduced 45.05%
61,433 $103,000
Q4 2020

Jan 14, 2021

SELL
$0.75 - $2.76 $5,571 - $20,504
-7,429 Reduced 6.23%
111,788 $177,000
Q3 2020

Oct 26, 2020

BUY
$0.61 - $1.17 $4,271 - $8,192
7,002 Added 6.24%
119,217 $96,000
Q2 2020

Aug 10, 2020

BUY
$0.47 - $0.72 $6,654 - $10,194
14,159 Added 14.44%
112,215 $71,000
Q1 2020

Apr 29, 2020

BUY
$0.36 - $0.74 $2,449 - $5,035
6,805 Added 7.46%
98,056 $40,000
Q4 2019

Jan 24, 2020

BUY
$0.35 - $0.58 $12,842 - $21,281
36,693 Added 67.26%
91,251 $53,000
Q3 2019

Nov 01, 2019

BUY
$0.38 - $0.52 $2,278 - $3,117
5,996 Added 12.35%
54,558 $27,000
Q2 2019

Jul 26, 2019

BUY
$0.39 - $0.7 $2,359 - $4,235
6,051 Added 14.23%
48,562 $20,000
Q1 2019

Apr 12, 2019

BUY
$0.43 - $0.68 $3,745 - $5,923
8,711 Added 25.77%
42,511 $23,000
Q4 2018

Jan 24, 2019

BUY
$0.39 - $0.7 $5,465 - $9,809
14,013 Added 70.82%
33,800 $16,000
Q3 2018

Oct 24, 2018

BUY
$0.44 - $3.02 $2,109 - $14,477
4,794 Added 31.97%
19,787 $10,000
Q2 2018

Aug 03, 2018

BUY
$1.66 - $3.82 $793 - $1,825
478 Added 3.29%
14,993 $30,000
Q1 2018

May 01, 2018

BUY
$2.16 - $3.48 $31,352 - $50,512
14,515 New
14,515 $49,000

Others Institutions Holding AMPE

# of Institutions
1
Shares Held
96.6K
Call Options Held
0
Put Options Held
0

About Ampio Pharmaceuticals, Inc.


  • Ticker AMPE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,287,008
  • Description
  • Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an...
More about AMPE
Track This Portfolio

Track Traynor Capital Management, Inc. Portfolio

Follow Traynor Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Traynor Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Traynor Capital Management, Inc. with notifications on news.